HomeInsightsStock Comparison

Alkem Laboratories Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Alkem Laboratories Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 09, 2025

Key Highlights

  • The Latest Trading Price of Alkem Laboratories Ltd is ₹ 4938 as of 08 May 15:30.
  • The P/E Ratio of Alkem Laboratories Ltd changed from 24.7 on March 2020 to 32.9 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Alkem Laboratories Ltd changed from ₹ 27844 crore on March 2020 to ₹ 59067 crore on March 2024 . This represents a CAGR of 16.23% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Alkem Laboratories Ltd for the Dec '24 is ₹ 3467 crore as compare to the Sep '24 revenue of ₹ 3549 crore. This represent the decline of -2.31% The revenue of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 1959 crore as compare to the Sep '24 revenue of ₹ 2037 crore. This represent the decline of -3.84%.
  • The ebitda of Alkem Laboratories Ltd for the Dec '24 is ₹ 852.38 crore as compare to the Sep '24 ebitda of ₹ 887.31 crore. This represent the decline of -3.94% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '24 is ₹ 358.5 crore as compare to the Sep '24 ebitda of ₹ 416.53 crore. This represent the decline of -13.93%.
  • The net profit of Alkem Laboratories Ltd changed from ₹ 287.81 crore to ₹ 640.79 crore over 7 quarters. This represents a CAGR of 57.99% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 140.97 crore to ₹ 156.09 crore over 7 quarters. This represents a CAGR of 5.99% .
  • The Dividend Payout of Alkem Laboratories Ltd changed from 23.64 % on March 2020 to 27.37 % on March 2024 . This represents a CAGR of 2.97% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 25.8 % on March 2020 to 22.53 % on March 2024 . This represents a CAGR of -2.67% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alkem Laboratories Ltd

  • Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
  • The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
  • The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
  • With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales.
  • The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.

About Emcure Pharmaceuticals Ltd

  • Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
  • Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada.

Alkem Laboratories Ltd News Hub

News

Alkem MedTech acquires Bombay Ortho Industries

Alkem Laboratories announced that its wholly owned subsidiary, Alkem MedTech has completed...

Read more

17 Apr 2025 09:43

News

Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho

In February this year, Alkem Medtech had executed a binding offer outlining the terms and ...

Read more

17 Apr 2025 14:49

News

Alkem Lab gains as Bioequivalence Center clears USFDA inspection without observations

The inspection, conducted from March 10 to March 13, 2025, concluded that no Form 483 had ...

Read more

17 Mar 2025 09:57

News

Alkem Lab's Bioequivalence Center clears USFDA inspection without observations

The inspection concluded that no Form 483 had been issued. Alkem Laboratories is engaged i...

Read more

15 Mar 2025 12:44

News

Alkem Laboratories launches generic empagliflozin in India

Alkem Laboratories announced the launch of generic empagliflozin and its combinations in I...

Read more

12 Mar 2025 10:26

News

Alkem Laboratories launches generic Empagliflozin in India

The products will be available at prices approximately 80% lower than those of the innovat...

Read more

12 Mar 2025 10:34

Emcure Pharmaceuticals Ltd News Hub

News

Emcure Pharma's pune facility receives VAI status from USFDA

The company received the Establishment Inspection Report (EIR) from the USFDA following an...

Read more

21 Apr 2025 11:09

News

Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset P...

Read more

04 Apr 2025 12:28

News

Emcure Pharma's European arm acquires Manx Healthcare for '19.7 million

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Gener...

Read more

04 Apr 2025 14:05

News

Emcutix Biopharmaceuticals inks in-licensing agreement with WiQo

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced...

Read more

02 Apr 2025 10:35

News

Emcure Pharmaceuticals forays into daily supplements space

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expan...

Read more

10 Mar 2025 19:33

News

Emcure Pharma's Maharashtra facility gets 2 USFDA observations

According to an exchange filing, the inspection was conducted at the company's Active Phar...

Read more

26 Feb 2025 13:23

SWOT Analysis Of Alkem Laboratories Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alkem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Emcure Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Alkem Laboratories Ltd is 59,049 Cr while Market cap of Emcure Pharmaceuticals Ltd is 19,364 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd?

As of May 9, 2025, the Alkem Laboratories Ltd stock price is INR ₹4938.7. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1021.95.

How do dividend payouts of Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions